Hypoglycemia risk is generally low with GLP-1 agonists when used as monotherapy, as their glucose-lowering effect is glucose-dependent
Is it safe to stop and start Wegovy
Animal studies have shown that GLP-1 receptor activation reduces beta-amyloid plaque accumulation, potentially preventing the damage that leads to Alzheimers
It enhances insulin secretion in response to high blood sugar levels, slows down gastric emptying, and reduces the production of glucose in the liver
When compared to specific drugs like DPP-4 inhibitors and sulfonylureas, the risk was even greaterabout 18% and 25% higher, respectively
[04:03-04:21] if you like this content, like subscribe, check us out at WWW nutritional physical therapy dot com